Search

Your search keyword '"Massuti, Bartomeu"' showing total 13 results

Search Constraints

Start Over You searched for: Author "Massuti, Bartomeu" Remove constraint Author: "Massuti, Bartomeu" Topic non-small-cell lung carcinoma Remove constraint Topic: non-small-cell lung carcinoma
13 results on '"Massuti, Bartomeu"'

Search Results

1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.

2. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.

Catalog

Books, media, physical & digital resources

3. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.

4. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.

5. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

6. Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.

7. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.

8. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).

9. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.

10. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.

11. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer.

12. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection

13. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).